Design, Synthesis, Biological Evaluation and In Silico Studies of Pyrazole-Based NH2-Acyl Oseltamivir Analogues as Potent Neuraminidase Inhibitors

被引:9
作者
Ye, Jiqing [1 ]
Lin, Lin [2 ]
Xu, Jinyi [3 ,4 ]
Chan, Paul Kay-sheung [2 ,5 ]
Yang, Xiao [2 ]
Ma, Cong [1 ]
机构
[1] Hong Kong Polytech Univ, Dept Appl Biol & Chem Technol, State Key Lab Chem Biol & Drug Discovery, Kowloon, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Microbiol, Shatin, Hong Kong, Peoples R China
[3] China Pharmaceut Univ, State Key Lab Nat Med, 24 Tong Jia Xiang, Nanjing 210009, Peoples R China
[4] China Pharmaceut Univ, Dept Med Chem, 24 Tong Jia Xiang, Nanjing 210009, Peoples R China
[5] Chinese Univ Hong Kong, Stanley Ho Ctr Emerging Infect Dis, Shatin, Hong Kong, Peoples R China
关键词
influenza virus; neuraminidase inhibitor; 150-cavity; oseltamivir derivatives; pyrazole;
D O I
10.3390/ph14040371
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Oseltamivir represents one of the most successful neuraminidase (NA) inhibitors in the current anti-influenza therapy. The 150-cavity of NA was identified as an additional binding pocket, and novel NA inhibitors have been designed to occupy the 150-cavity based on the structure information of oseltamivir carboxylate (OC) in complex with NA. In this study, a series of C-5-NH2-acyl derivatives of OC containing the pyrazole moiety were synthesized. Several derivatives exhibited substantial inhibitory activity against NA. Moreover, in silico ADME evaluation indicated that the derivatives were drug-like with higher oral absorption rates and greater cell permeability than OC. Additionally, molecular docking studies revealed that the derivatives interacted with both the NA enzyme active site and 150-cavity as expected. The results provided useful information for further structural optimization of OC.
引用
收藏
页数:20
相关论文
共 24 条
[1]   Copper-diamine-catalyzed N-arylation of pyrroles, pyrazoles, indazoles, imidazoles, and triazoles [J].
Antilla, JC ;
Baskin, JM ;
Barder, TE ;
Buchwald, SL .
JOURNAL OF ORGANIC CHEMISTRY, 2004, 69 (17) :5578-5587
[2]   The biology of influenza viruses [J].
Bouvier, Nicole M. ;
Palese, Peter .
VACCINE, 2008, 26 :D49-D53
[3]   The molecular epidemiology of influenza viruses [J].
Cox, NJ ;
Bender, CA .
SEMINARS IN VIROLOGY, 1995, 6 (06) :359-370
[4]   Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study [J].
Dawood, Fatimah S. ;
Iuliano, A. Danielle ;
Reed, Carrie ;
Meltzer, Martin I. ;
Shay, David K. ;
Cheng, Po-Yung ;
Bandaranayake, Don ;
Breiman, Robert F. ;
Brooks, W. Abdullah ;
Buchy, Philippe ;
Feikin, Daniel R. ;
Fowler, Karen B. ;
Gordon, Aubree ;
Nguyen Tran Hien ;
Horby, Peter ;
Huang, Q. Sue ;
Katz, Mark A. ;
Krishnan, Anand ;
Lal, Renu ;
Montgomery, Joel M. ;
Molbak, Kare ;
Pebody, Richard ;
Presanis, Anne M. ;
Razuri, Hugo ;
Steens, Anneke ;
Tinoco, Yeny O. ;
Wallinga, Jacco ;
Yu, Hongjie ;
Vong, Sirenda ;
Bresee, Joseph ;
Widdowson, Marc-Alain .
LANCET INFECTIOUS DISEASES, 2012, 12 (09) :687-695
[5]   Synthesis, anti-HSV-1, and cytotoxic activities of some new pyrazole- and isoxazole-based heterocycles [J].
Dawood, Kamal M. ;
Abdel-Gawad, Hassan ;
Mohamed, Hanan A. ;
Badria, Farid A. .
MEDICINAL CHEMISTRY RESEARCH, 2011, 20 (07) :912-919
[6]   Influenza Hemagglutinin and Neuraminidase Membrane Glycoproteins [J].
Gamblin, Steven J. ;
Skehel, John J. .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (37) :28403-28409
[7]  
Greener Mark, 2009, Nurs Times, V105, P22
[8]   Baloxavir and Treatment-Emergent Resistance: Public Health Insights and Next Steps [J].
Gubareva, Larisa V. ;
Fry, Alicia M. .
JOURNAL OF INFECTIOUS DISEASES, 2020, 221 (03) :337-339
[9]   Antivirals for influenza in healthy adults: systematic review [J].
Jefferson, T ;
Demicheli, V ;
Rivetti, D ;
Jones, M ;
Di Pietrantonj, C ;
Rivetti, A .
LANCET, 2006, 367 (9507) :303-313
[10]   Influenza pandemics of the 20th century [J].
Kilbourne, ED .
EMERGING INFECTIOUS DISEASES, 2006, 12 (01) :9-14